Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
[en] A hepatitis E virus (HEV) vaccine would be valuable to reduce the morbidity and mortality associated with the infection in endemic areas. HEV pseudocapsids and epidermal delivery of HEV ORF2 DNA vaccine by gene-gun have been shown to confer protection against virus challenge in monkeys. Vectorization of a DNA vaccine by virus-like particles is a new immunization approach. We report here the successful immunization of mice with two ORF2 genes encapsidated into human papillomavirus type 31 virus-like particles. The HEV genes ORF2(112-660) and ORF2(112-608) were optimized for expression in mammalian cells and inserted in a baculovirus-derived vector for expression in insect cells. When expressed in Sf21 insect cells, ORF2(112-660) led to the production of irregular 15 nm particles that accumulated in the cytoplasm of the cells, whereas ORF2(112-608) induced the production of 18nm particles that were present in both the cell culture medium and the cell cytoplasm. Anti-HEV immune responses were higher for the 15 nm particles (HEV112-660) than that for to the 18 nm particles (HEV112-608). Delivery into mice of two HEV ORF2 genes via a papillomavirus VLP was very effective in the induction of anti-HEV antibodies. In addition, an effective immune response to human papillomavirus capsids occurred. These engineered pseudoviruses were thus demonstrated to induce immune responses to both hepatitis E virus and human papillomavirus when they were administered to mice intramuscularly.
Disciplines :
Immunology & infectious disease
Author, co-author :
Renoux, Virginie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Fleury, Maxime J J
Bousarghin, Latifa
Gaitan, Julien
Sizaret, Pierre*-Yves
Touze, Antoine
Coursaget, Pierre
Language :
English
Title :
Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Panda S.K., Thakral D., and Rehman S. Hepatitis E virus. Rev Med Virol 17 (2007) 151-180
Purcell R.H., and Tsarev S.A. Seroepidemiology of hepatitis E. In: Buisson Y., Coursaget P., and Kane M. (Eds). Enterically-transmitted hepatitis viruses (1996), La Simarre, Tours 153-166
Krawczynski K., Aggarwal R., Kamili S., and Hepatitis E. Infect Dis Clin N Am 14 (2000) 669-687
Krawczynski K., Aggarwal R., and Kalimi S. Epidemiology, clinical and pathologic features, diagnosis, and experimental models. In: Thomas H.C., Lemon S., and Zuckerman A.J. (Eds). Viral hepatitis (2005), Blackwell Publishing, Malden, MA 624-634
Tong M.J., Roué R., N'Gawara M.N., Desmare J., Buisson Y., and Coursaget P. Clinical aspects of HAV and HEV infections: a comparison. In: Buisson Y., Coursaget P., and Kane M. (Eds). Enterically-transmitted hepatitis viruses (1996), La Simarre, Tours 1-10
Arankalle V.A., Ticehurst J., Sreenivasan M.A., Kapikian A.Z., Popper H., Pavri K.M., et al. Aetiological association of a virus-like particle with enterically transmitted non-A, non-B hepatitis. Lancet 1 (1988) 550-554
Khuroo M.S., and Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 10 (2003) 61-69
Boccia D., Guthmann J.P., Klovstad H., Hamid N., Tatay M., Ciglenecki I., et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis 42 (2006) 1679-1684
Coursaget P., Buisson Y., N'Gawara M.N., Van Cuyck-Gandre H., and Roue R. Role of hepatitis E virus in sporadic cases of acute and fulminant hepatitis in an endemic area (Chad). Am J Trop Med Hyg 58 (1998) 330-334
Hamid S.S., Atiq M., Shehzad F., Yasmeen A., Nissa T., Salam A., et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 36 (2002) 474-478
Zafrullah M., Ozdener M.H., Panda S.K., and Jameel S. The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. J Virol 71 (1997) 9045-9053
Tyagi S., Korkaya H., Zafrullah M., Jameel S., and Lal S.K. The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2. J Biol Chem 277 (2002) 22759-22767
Emerson S.U., and Purcell R.H. Hepatitis E virus. Rev Med Virol 13 (2003) 145-154
Purdy M.A., McCaustland K.A., Krawczynski K., Spelbring J., Reyes G.R., and Bradley D.W. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol 41 (1993) 90-94
Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L., et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci USA 91 (1994) 10198-10202
Shrestha M.P., Scott R.M., Joshi D.M., Mammen Jr. M.P., Thapa G.B., Thapa N., et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356 (2007) 895-903
Li T.C., Yamakawa Y., Suzuki K., Tatsumi M., Razak M.A., Uchida T., et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71 (1997) 7207-7213
Fuerst T.R., Yarbough P.O., Zhang Y., McAtee A., Tam A., Lifson J., et al. Prevention of hepatitis E using a novel ORF2-2 subunit vaccine. In: Buisson Y., Coursaget P., and Kane M. (Eds). Enterically-transmitted hepatitis viruses (1996), La Simarre, Tours 384-392
Yarbough P., Krawczynski K., and Tam A. Prevention of hepatitis E using r62k subunit vaccine: full protection against heterologous HEV chalenge in cynomolgus macaques. In: Rizetto M., Purcell R., Gerin J., and Verme G. (Eds). Viral hepatitis and liver disease (1997), Minerva Medica, Turin 650-655
Kamili S., Spelbring J., Carson D., and Krawczynski K. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. J Infect Dis 189 (2004) 258-264
Kamili S., Spelbring J., and Krawczynski K. DNA vaccination against hepatitis E virus infection in cynomolgus macaques. J Gastroenterol Hepatol 17 Suppl. 3 (2002) S365-S369
Sapp M., Volpers C., and Streeck R.E. Synthesis, properties and applications of papillomavirus-like particles. Intervirology 39 (1996) 49-53
Lowy D.R., and Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 116 (2006) 1167-1173
Ramqvist T., Andreasson K., and Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 7 (2007) 997-1007
Touze A., and Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26 (1998) 1317-1323
Shi W., Liu J., Huang Y., and Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75 (2001) 10139-10148
Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 (2004) 751-757
Bousarghin L., Combita-Rojas A.L., Touze A., El Mehdaoui S., Sizaret P.Y., Bravo M.M., et al. Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol 40 (2002) 926-932
Fayad R., Zhang H., Quinn D., Huang Y., and Qiao L. Oral administration with papillomavirus pseudovirus encoding IL-2 fully restores mucosal and systemic immune responses to vaccinations in aged mice. J Immunol 173 (2004) 2692-2698
Zhang H., Fayad R., Wang X., Quinn D., and Qiao L. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol 78 October (2004) 10249-10257
Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
Tam A.W., Smith M.M., Guerra M.E., Huang C.C., Bradley D.W., Fry K.E., et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185 (1991) 120-131
Li T.C., Takeda N., Miyamura T., Matsuura Y., Wang J.C., Engvall H., et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol 79 (2005) 2999-3006
Fleury M.J.J., Touzé A., de Sanjosé S., Bosch F.X., Klaustermeiyer J., and Coursaget P. Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol 15 (2008) 172-175
Bousarghin L., Combita-Rojas A.L., Touze A., El Mehdaoui S., Sizaret P.Y., Bravo M.M., et al. Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol 40 (2004) 926-932
Hanslip S.J., Zaccai N.R., Middelberg A.P., and Falconer R.J. Assembly of human papillomavirus type-16 virus-like particles: multifactorial study of assembly and competing aggregation. Biotechnol Prog 22 (2006) 554-560
He J., Hoffman S.L., and Hayes C.G. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine 15 (1997) 357-362
Deshmukh T.M., Lole K.S., Tripathy A.S., and Arankalle V.A. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice. Vaccine 25 (2007) 4350-4360
Purcell R.H., Nguyen H., Shapiro M., Engle R.E., Govindarajan S., Blackwelder W.C., et al. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 21 (2003) 2607-2615
Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L., et al. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 15 (1997) 1834-1838
Tsarev S.A., Tsareva T.S., Emerson S.U., Kapikian A.Z., Ticehurst J., London W., and Purcell R.H. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J Infect Dis 168 (1993) 369-378
Combita A.L., Touzé A., Bousarghin L., Sizaret P.Y., Muñoz N., and Coursaget P. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204 (2001) 183-188
Kämper N., Day P.M., Nowak T., Selinka H.C., Florin L., Bolscher J., et al. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80 (2006) 759-768
Fleury M.J., Touzé A., Alvarez E., Carpentier G., Clavel C., Vautherot J.F., et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151 (2006) 1511-1523
El Mehdaoui S., Touzé A., Laurent S., Sizaret P.Y., Rasschaert D., and Coursaget P. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16. J Virol 74 (2000) 10332-10340
Malboeuf C.M., Simon D.A., Lee Y.E., Lankes H.A., Dewhurst S., Frelinger J.G., et al. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 25 (2007) 3270-3276
Combita A.L., Touzé A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 (2002) 6480-6486
Ishii Y., Ozaki S., Tanaka K., and Kanda T. Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. Virus Genes 31 (2005) 321-328
Schofield D.J., Glamann J., Emerson S.U., and Purcell R.H. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 74 (2000) 5548-5555
Riddell M.A., Li F., and Anderson D.A. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J Virol 74 (2000) 8011-8017
Li F., Riddell M.A., Seow H.F., Takeda N., Miyamura T., and Anderson D.A. Recombinant subunit ORF2.1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein. J Med Virol 60 (2000) 379-386
Yarbough P.O., Tam A.W., Fry K.E., Krawczynski K., McCaustland K.A., Bradley D.W., et al. Hepatitis E virus: identification of type-common epitopes. J Virol 65 (1991) 5790-5797
Touze A., Enogat N., Buisson Y., and Coursaget P. Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay. J Clin Microbiol 37 (1999) 438-441
Zhou Y.H., Purcell R.H., and Emerson S.U. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3 and 4. Vaccine 22 (2004) 2578-2585
Thönes N., and Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 369 (2007) 375-388
Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., and Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72 (1998) 8220-8229
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
